1
|
Hofman P, Calabrese F, Kern I, Adam J, Alarcão A, Alborelli I, Anton NT, Arndt A, Avdalyan A, Barberis M, Bégueret H, Bisig B, Blons H, Boström P, Brcic L, Bubanovic G, Buisson A, Caliò A, Cannone M, Carvalho L, Caumont C, Cayre A, Chalabreysse L, Chenard MP, Conde E, Copin MC, Côté JF, D'Haene N, Dai HY, de Leval L, Delongova P, Denčić-Fekete M, Fabre A, Ferenc F, Forest F, de Fraipont F, Garcia-Martos M, Gauchotte G, Geraghty R, Guerin E, Guerrero D, Hernandez S, Hurník P, Jean-Jacques B, Kashofer K, Kazdal D, Lantuejoul S, Leonce C, Lupo A, Malapelle U, Matej R, Merlin JL, Mertz KD, Morel A, Mutka A, Normanno N, Ovidiu P, Panizo A, Papotti MG, Parobkova E, Pasello G, Pauwels P, Pelosi G, Penault-Llorca F, Picot T, Piton N, Pittaro A, Planchard G, Poté N, Radonic T, Rapa I, Rappa A, Roma C, Rot M, Sabourin JC, Salmon I, Prince SS, Scarpa A, Schuuring E, Serre I, Siozopoulou V, Sizaret D, Smojver-Ježek S, Solassol J, Steinestel K, Stojšić J, Syrykh C, Timofeev S, Troncone G, Uguen A, Valmary-Degano S, Vigier A, Volante M, Wahl SGF, Stenzinger A, Ilié M. Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe. ESMO Open 2023; 8:101628. [PMID: 37713929 PMCID: PMC10594022 DOI: 10.1016/j.esmoop.2023.101628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2023] [Revised: 06/14/2023] [Accepted: 08/02/2023] [Indexed: 09/17/2023] Open
Abstract
BACKGROUND Testing for epidermal growth factor receptor (EGFR) mutations is an essential recommendation in guidelines for metastatic non-squamous non-small-cell lung cancer, and is considered mandatory in European countries. However, in practice, challenges are often faced when carrying out routine biomarker testing, including access to testing, inadequate tissue samples and long turnaround times (TATs). MATERIALS AND METHODS To evaluate the real-world EGFR testing practices of European pathology laboratories, an online survey was set up and validated by the Pulmonary Pathology Working Group of the European Society of Pathology and distributed to 64 expert testing laboratories. The retrospective survey focussed on laboratory organisation and daily EGFR testing practice of pathologists and molecular biologists between 2018 and 2021. RESULTS TATs varied greatly both between and within countries. These discrepancies may be partly due to reflex testing practices, as 20.8% of laboratories carried out EGFR testing only at the request of the clinician. Many laboratories across Europe still favour single-test sequencing as a primary method of EGFR mutation identification; 32.7% indicated that they only used targeted techniques and 45.1% used single-gene testing followed by next-generation sequencing (NGS), depending on the case. Reported testing rates were consistent over time with no significant decrease in the number of EGFR tests carried out in 2020, despite the increased pressure faced by testing facilities during the COVID-19 pandemic. ISO 15189 accreditation was reported by 42.0% of molecular biology laboratories for single-test sequencing, and by 42.3% for NGS. 92.5% of laboratories indicated they regularly participate in an external quality assessment scheme. CONCLUSIONS These results highlight the strong heterogeneity of EGFR testing that still occurs within thoracic pathology and molecular biology laboratories across Europe. Even among expert testing facilities there is variability in testing capabilities, TAT, reflex testing practice and laboratory accreditation, stressing the need to harmonise reimbursement technologies and decision-making algorithms in Europe.
Collapse
Affiliation(s)
- P Hofman
- Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Biobank Côte d'Azur BB-0033-00025, Louis Pasteur Hospital, IRCAN, Université Côte d'Azur, Nice, France.
| | - F Calabrese
- Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy
| | - I Kern
- Department of Pathology, University Clinic Golnik, Golnik, Slovenia
| | - J Adam
- Department of Pathology, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - A Alarcão
- IAP-PM, Institute of Anatomical and Molecular Pathology, Faculty of Medicine, University of Coimbra, 3004-504 Coimbra, Portugal
| | - I Alborelli
- Department of Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - N T Anton
- Department of Genetics, University Hospital Bichat-Claude Bernard, Paris University, Paris, France
| | - A Arndt
- Institute of Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm, Oberer Eselsberg 40, 89081 Ulm, Germany
| | - A Avdalyan
- Multidisciplinary Clinical Center "Kommunarka" of the Moscow Health Department, Moscow, Russia
| | - M Barberis
- Oncogenomics Unit, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy
| | - H Bégueret
- Department of Pathology, University Hospital of Bordeaux, Hôpital Haut-Lévêque, Pessac, France
| | - B Bisig
- Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - H Blons
- Pharmacogenomics and Molecular Oncology Unit, Biochemistry Department, Assistance Publique-Hopitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France
| | - P Boström
- Department of Pathology, Turku University Hospital, Turku, Finland
| | - L Brcic
- Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria
| | - G Bubanovic
- Laboratory for Molecular Pathology, Department of Pathology, University of Zagreb School of Medicine and University Hospital Centre Zagreb, Zagreb, Croatia
| | - A Buisson
- Department of Biopathology, Centre Léon Bérard, Lyon, France
| | - A Caliò
- Department of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, Verona, Italy
| | - M Cannone
- Inter-Hospital Pathology Division, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), MultiMedica, Milan, Italy
| | - L Carvalho
- IAP-PM, Institute of Anatomical and Molecular Pathology, Faculty of Medicine, University of Coimbra, 3004-504 Coimbra, Portugal
| | - C Caumont
- Department of Tumor Biology, University Hospital of Bordeaux, Hospital Haut-Lévêque, Pessac, France
| | - A Cayre
- Department of Biopathology, Jean Perrin Centre, Clermont-Ferrand, France
| | - L Chalabreysse
- Department of Pathology, Groupement Hospitalier Est, Bron, France
| | - M P Chenard
- Department of Pathology, University Hospital of Strasbourg, 67098 Strasbourg, France
| | - E Conde
- Department of Pathology, 12 de Octubre University Hospital, Universidad Complutense de Madrid, Research Institute 12 de Octubre University Hospital (i+12), CIBERONC, Madrid, Spain
| | - M C Copin
- Department of Pathology, Université d'Angers, Centre Hospitalier Universitaire d'Angers, Angers, France
| | - J F Côté
- Department of Pathology, Institut Mutualiste Montsouris, Paris, France
| | - N D'Haene
- Department of Pathology, Erasme Hospital, HUB ULB, Brussels, Belgium
| | - H Y Dai
- Department of Pathology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway
| | - L de Leval
- Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - P Delongova
- Institute of Molecular and Clinical Pathology and Medical Genetics, Faculty of Medicine, University Hospital Ostrava, Ostrava, Czech Republic
| | | | - A Fabre
- Department of Histopathology, St. Vincent's University Hospital, University College Dublin School of Medicine, Dublin, Ireland
| | - F Ferenc
- Department of Pathology, University of Oradea, Oradea, Romania
| | - F Forest
- Department of Pathology, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - F de Fraipont
- Medical Unit of Molecular Genetic (Hereditary Diseases and Oncology), Grenoble University Hospital, Grenoble, France
| | - M Garcia-Martos
- Department of Pathology, Gregorio Marañón General University Hospital, Madrid, Spain
| | - G Gauchotte
- Department of Biopathology, CHRU-ICL, CHRU Nancy, Vandoeuvre-lès-Nancy, France
| | - R Geraghty
- Department of Histopathology, St. Vincent's University Hospital, University College Dublin School of Medicine, Dublin, Ireland
| | - E Guerin
- Department of Molecular Cancer Genetics, Laboratory of Biochemistry and Molecular Biology, University Hospital of Strasbourg, Strasbourg, France
| | - D Guerrero
- Biomedical Research Centre, Navarra Health Service, Pamplona, Navarra, Spain
| | - S Hernandez
- Department of Pathology, 12 de Octubre University Hospital, Universidad Complutense de Madrid, Research Institute 12 de Octubre University Hospital (i+12), CIBERONC, Madrid, Spain
| | - P Hurník
- Institute of Molecular and Clinical Pathology and Medical Genetics, Faculty of Medicine, University Hospital Ostrava, Ostrava, Czech Republic
| | - B Jean-Jacques
- Department of Pathology, CHU de Caen Côte de Nacre, Caen, France
| | - K Kashofer
- Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria
| | - D Kazdal
- Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center for Lung Research (DZL), Heidelberg, Germany
| | - S Lantuejoul
- Department of Biopathology, Centre Leon Berard Unicancer and Pathology Research Platform, Cancer Research Center of Lyon (CRCL), Lyon, France
| | - C Leonce
- Department of Pathology, Groupement Hospitalier Est, Bron, France
| | - A Lupo
- Department of Pathology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France
| | - U Malapelle
- Department of Public Health, University of Naples Federico II, Naples, Italy
| | - R Matej
- Department of Pathology and Molecular Medicine, Thomayer University Hospital, Prague, Czech Republic
| | - J L Merlin
- Department of Biopathology, Institut de Cancérologie de Lorraine, University of Lorraine, Vandoeuvre-Les-Nancy, France
| | - K D Mertz
- Institute of Pathology, Cantonal Hospital Baselland, Liestal, Switzerland
| | - A Morel
- Department of Innate Immunity and Immunotherapy, Institut de Cancérologie de l'Ouest - Centre Paul Papin, Angers, France
| | - A Mutka
- HUSLAB, Department of Pathology, Helsinki University Hospital, Helsinki, Finland
| | - N Normanno
- Cell Biology and Biotherapy Unit, INT-Fondazione Pascale, Via M. Semmola, Naples, Italy
| | - P Ovidiu
- Department of Pathology, University of Oradea, Oradea, Romania
| | - A Panizo
- Department of Pathology, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
| | - M G Papotti
- Division of Pathology, University Hospital Città Della Salute, Turin, Italy
| | - E Parobkova
- Department of Pathology and Molecular Medicine, Thomayer University Hospital, Prague, Czech Republic
| | - G Pasello
- Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - P Pauwels
- Department of Pathology, University Hospital Antwerp and University of Antwerp, Antwerp, Belgium
| | - G Pelosi
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - F Penault-Llorca
- Department of Pathology, Clermont Auvergne University, "Molecular Imaging and Theranostic Strategies", Center Jean Perrin, Montalembert, Clermont-Ferrand, France
| | - T Picot
- Department of Pathology, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - N Piton
- Department of Pathology, Rouen University Hospital, France and Normandie University, UNIROUEN, Inserm U1245, Rouen, France
| | - A Pittaro
- Division of Pathology, University Hospital Città Della Salute, Turin, Italy
| | - G Planchard
- Department of Pathology, CHU de Caen Côte de Nacre, Caen, France
| | - N Poté
- Department of Pathology, Hospital Bichat Bichat, Assistance Publique Hôpitaux de Paris; Université Paris Cité, Paris, France
| | - T Radonic
- Department of Pathology, Amsterdam University Medical Center, VUMC, University of Amsterdam, Amsterdam, Netherlands
| | - I Rapa
- Pathology Unit, San Luigi Hospital, Orbassano Turin, Italy
| | - A Rappa
- Oncogenomics Unit, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy
| | - C Roma
- Cell Biology and Biotherapy Unit, INT-Fondazione Pascale, Via M. Semmola, Naples, Italy
| | - M Rot
- Department of Pathology, University Clinic Golnik, Golnik, Slovenia
| | - J C Sabourin
- Department of Pathology, Rouen University Hospital, France and Normandie University, UNIROUEN, Inserm U1245, Rouen, France
| | - I Salmon
- Department of Pathology, Erasme Hospital, HUB ULB, Brussels, Belgium; CurePath, Jumet, Belgium
| | - S Savic Prince
- Department of Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - A Scarpa
- Department of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, Verona, Italy
| | - E Schuuring
- Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
| | - I Serre
- Department of Pathology, Gui de Chauliac Hospital, Montpellier University Medical Center, University of Montpellier, 80 Avenue Augustin Fliche, Montpellier, France
| | - V Siozopoulou
- Department of Pathology, University Hospital Antwerp and University of Antwerp, Antwerp, Belgium
| | - D Sizaret
- Department of Pathology, CHRU Tours - Hôpital Trousseau, Chambray-lès-Tours, France
| | - S Smojver-Ježek
- Division for Pulmonary Cytology, Department of Pathology and Cytology, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - J Solassol
- Solid Tumour Laboratory, Pathology and Oncobiology Department, CHU Montpellier, University of Montpellier, Montpellier, France
| | - K Steinestel
- Institute of Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm, Oberer Eselsberg 40, 89081 Ulm, Germany
| | - J Stojšić
- Department of Thoracic Pathology, Section of Pathology, University Clinical Centre of Serbia, Belgrade, Serbia
| | - C Syrykh
- Department of Pathology, IUC-T-Oncopole, Toulouse, France
| | - S Timofeev
- Multidisciplinary Clinical Center "Kommunarka" of the Moscow Health Department, Moscow, Russia
| | - G Troncone
- Department of Pathology, University of Oradea, Oradea, Romania
| | - A Uguen
- Department of Pathological Anatomy and Cytology, CHRU de Brest, Brest, France; LBAI, UMR1227, INSERM, University of Brest, CHU de Brest, Brest, France
| | - S Valmary-Degano
- Department of Pathology, Institute for Advanced Biosciences, CHU Grenoble Alpes, Université Grenoble Alpes, Grenoble, France
| | - A Vigier
- Department of Pathology, IUC-T-Oncopole, Toulouse, France
| | - M Volante
- Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Turin, Italy
| | - S G F Wahl
- Department of Pathology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway
| | - A Stenzinger
- Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center for Lung Research (DZL), Heidelberg, Germany
| | - M Ilié
- Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Biobank Côte d'Azur BB-0033-00025, Louis Pasteur Hospital, IRCAN, Université Côte d'Azur, Nice, France
| |
Collapse
|
2
|
Nadour Z, Rosenbaum B, Blons H, Loriot MA, Paul JL, Pallet N. [Clinical, biochemical and epidemiological features of macro-AST preceding inflammatory bowel disease diagnosis by several years]. Rev Med Interne 2023; 44:259-262. [PMID: 36958982 DOI: 10.1016/j.revmed.2023.03.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2022] [Accepted: 03/05/2023] [Indexed: 03/25/2023]
Abstract
INTRODUCTION An isolated elevation of aspartate aminotransferase (AST) is a diagnostic issue. Macro-aspartate aminotransferase (macro-AST) corresponds to the formation of complexes between AST and immunoglobulins. CASE REPORT We report the case of a patient with macro-AST identified several years before the onset of inflammatory bowel disease (IBD). A 6-year retrospective analysis in our laboratory identified only one case out of 42 540 adult patients. CONCLUSION The objective of this work is to increase awareness of this benign disorder among clinicians and biologists, as well as to aid in prescribing only the required tests.
Collapse
Affiliation(s)
- Z Nadour
- Service de biochimie, hôpital européen Georges-Pompidou, assistance publique-hôpitaux de Paris (AP-HP), 75013 Paris, France.
| | - B Rosenbaum
- Service de gastroentérologie et endoscopie digestive, hôpital européen Georges-Pompidou, assistance publique-hôpitaux de Paris (AP-HP), 75013 Paris, France
| | - H Blons
- Service de biochimie, hôpital européen Georges-Pompidou, assistance publique-hôpitaux de Paris (AP-HP), 75013 Paris, France
| | - M A Loriot
- Service de biochimie, hôpital européen Georges-Pompidou, assistance publique-hôpitaux de Paris (AP-HP), 75013 Paris, France
| | - J-L Paul
- Service de biochimie, hôpital européen Georges-Pompidou, assistance publique-hôpitaux de Paris (AP-HP), 75013 Paris, France
| | - N Pallet
- Service de biochimie, hôpital européen Georges-Pompidou, assistance publique-hôpitaux de Paris (AP-HP), 75013 Paris, France
| |
Collapse
|
3
|
Boige V, Francois E, Blons H, Ben Abdelghani M, Phelip J, Ly Lebrun V, Mineur L, Galais M, Villing AL, Hautefeuille V, Miglianico L, de la Fouchardiere C, Genet D, Levasseur N, Lachaux N, Gourgou S, Castan F, Bouche O. 387P Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Final results of the randomized phase II TIME-PRODIGE 28 UNICANCER study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
4
|
Blons H, Polivka V, Francois E, Ben Abdelghani M, Phelip J, Lebrun-Ly V, Mineur L, Garinet S, Farace F, Lachaux N, Gourgou S, Bouche O, Boige V. 387MO Tumour mutation profiles and circulating tumour cells in metastatic colorectal cancer patients treated with FOLFIRI + cetuximab: A prospective ancillary study of the UNICANCER PRODIGE-28 trial. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.909] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
5
|
Blons H, Oudart JB, Merlio JP, Debieuvre D, de Fraipont F, Audigier-Valette C, Escande F, Hominal S, Bringuier PP, Fraboulet-Moreau S, Ouafik L, Moro-Sibilot D, Lemoine A, Langlais A, Missy P, Morin F, Souquet PJ, Barlesi F, Cadranel J, Beau-Faller M. PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project. Lung Cancer 2020; 151:69-75. [PMID: 33248711 DOI: 10.1016/j.lungcan.2020.11.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2020] [Revised: 10/22/2020] [Accepted: 11/10/2020] [Indexed: 01/09/2023]
Abstract
OBJECTIVES Tumor mutation screening is standard of care for patients with stage IV NSCLC. Since a couple of years, widespread NGS approaches used in routine diagnostics to detect driver mutations such as EGFR, KRAS, BRAF or MET allows the identification of other alterations that could modulated the intensity or duration of response to targeted therapies. The prevalence of co-occurring alterations that could affect response or prognosis as not been largely analyzed in clinical settings and large cohorts of patients. Thanks to the IFCT program "Biomarkers France", a collection of samples and data at a nation-wide level was available to test the impact of co-mutations on first line EGFR TKI in patients with EGFR mutated cancers. MATERIALS AND METHODS Targeted NGS was assessed on available (n = 208) samples using the Ion AmpliSeq™ Cancer Hotspot Panel v2 to screen for mutations in 50 different cancer genes. RESULTS This study showed that PTEN inactivating mutations, ATM alterations, IDH1 mutations and complex EGFR mutations were predictors of short PFS in patients with a stage 4 lung adenocarcinoma receiving first line EGFR TKI and that PTEN, ATM, IDH1 and KRAS mutations as well as alterations in the MAPK pathway were related to shorter OS. CONCLUSION These findings may lead to new treatment options in patients with unfavorable genotypes to optimize first line responses.
Collapse
Affiliation(s)
- H Blons
- HEGP, Biochimie UF de Pharmacogénétique et Oncologie Moléculaire, Paris, France; Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, France
| | - J-B Oudart
- HEGP, Biochimie UF de Pharmacogénétique et Oncologie Moléculaire, Paris, France
| | - J-P Merlio
- Tumor Bank and Tumor Biology Department, CHU Bordeaux, Bordeaux France; INSERM U1053, Univ. Bordeaux, Bordeaux France
| | - D Debieuvre
- Service de pneumologie, GHRMSA-Hôpital Emile Muller, Mulhouse, France
| | - F de Fraipont
- Unité de Génétique Moléculaire, Maladies Héréditaires et Oncologie, CHU Grenoble Alpes, Grenoble, France
| | | | - F Escande
- Laboratoire de Biochimie et Biologie Moléculaire, CHU Lille, France
| | - S Hominal
- Centre Hospitalier Annecy-Genevois, Epagny-Metz Tessy, France
| | - P-P Bringuier
- Institut de Pathologie Multi-Sites des Hospices Civils de Lyon - Site Est, Plateforme de Pathologie Moléculaire, Hospices Civils de Lyon, Lyon, France; Université Claude Bernard Lyon 1, Lyon, France
| | | | - L Ouafik
- Aix Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France; APHM, CHU Nord, Service de Transfert d'Oncologie Biologique, Marseille, France
| | - D Moro-Sibilot
- Unité d'Oncologie Thoracique, Service Hospitalier Universitaire Pneumologie Physiologie Pôle Thorax et Vaisseaux, CHU Grenoble Alpes, Grenoble, France
| | - A Lemoine
- Biochimie et Oncogénétique INSERM UMR-S1193, Hôpital Paul Brousse, Hôpitaux Universitaires Paris-Sud, Villejuif, France
| | - A Langlais
- Department of Biostatistics, French Cooperative Thoracic Intergroup, Paris, France
| | - P Missy
- Clinical Research Unit, French Cooperative Thoracic Intergroup, Paris, France
| | - F Morin
- Clinical Research Unit, French Cooperative Thoracic Intergroup, Paris, France
| | - P-J Souquet
- Service de pneumologie aiguë spécialisée et cancérologie thoracique, Hospices Civils de Lyon, Centre hospitalier Lyon-Sud, Pierre-Bénite, France
| | - F Barlesi
- Aix Marseille University, INSERM, CNRS, CRCM, APHM, Multidisciplinary Oncology & Therapeutic Innovations Department, Marseille, France
| | - J Cadranel
- AP-HP, Hôpital Tenon, Service de Pneumogie, GRC 04 Theranoscan, Sorbonne Université, Paris, France
| | - M Beau-Faller
- Laboratory of Biochemistry and Molecular Biology, Centre Hospitalier Universitaire de Strasbourg, Hôpital de Hautepierre, Strasbourg, France; IRFAC UMR-S1113, Inserm, Université de Strasbourg, Strasbourg, France.
| | | |
Collapse
|
6
|
|
7
|
Boulle G, Velut Y, Mansuet-Lupo A, Gibault L, Blons H, Fournel L, Boni A, Cremer I, Wislez M, Duchatelle V, Trédaniel J, Hammond SA, Herbst R, Alifano M, Giraud P, Damotte D. Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non-small-cell lung carcinoma. Eur J Cancer 2020; 135:221-229. [PMID: 32610210 DOI: 10.1016/j.ejca.2020.04.040] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2020] [Revised: 04/18/2020] [Accepted: 04/27/2020] [Indexed: 10/24/2022]
Abstract
BACKGROUND Radiotherapy is a standard of care for locally advanced stage III N2 non-small-cell lung carcinoma (NSCLC) combined with surgery/chemotherapy. Radiotherapy is hypothesised to induce tumour immunogenic cell death, to release neoantigen resulting in intra-tumoural immune infiltration and abscopal effect. Conversely, it has not been demonstrated if immune cells are necessary to drive radiotherapy efficacy and predict patient's survival. PATIENTS AND METHODS We retrospectively analysed tumour samples and clinical data from 113 patients, 89 resected (PORT) and 24 non-resected (DRC) N2-NSCLC treated with chemotherapy and radiotherapy (same radiotherapy department from 2002 to 2015). The immune environment was characterised with in situ multiplex staining (CD8, FoxP3, PD-L1 and cytokeratin) and correlated with clinical data and survival. RESULTS High density of CD8+ T cells was associated with OS (p = 0.04, HR = 1.93 [0.99-3.78]) and DFS (p = 0.003, HR = 2.42 [1.31-4.47]) in the PORT. High density of CD8+/FoxP3+ double positive cells was associated with OS (p = 0.01, HR = 1.97 [1.11-3.48]) in the whole population, with OS (p = 0.05, HR = 1.92 [0.98-3.74]) and PFS (p = 0.03, HR = 1.83 [1.03-3.23]) in the PORT without reaching significance for the DRC. Intermediate PD-L1 expression in tumour cells (TPS = 1-49%) was associated with a higher survival in the PORT. CONCLUSIONS Intra-tumoural CD8+ T cell and particularly CD8+/FoxP3+ double positive T cell densities predict survival in stage III N2-NSCLC suggesting the need for a pre-existing intra-tumour immunity to mediate the action of radiotherapy. Density of CD8+/FoxP3+ cells was the best predictor of patient's survival in multivariate analysis and could represent a biomarker of radiotherapy efficacy.
Collapse
Affiliation(s)
- G Boulle
- Institut National de La Santé et de La Recherche Médicale (INSERM), UMRS 1138, Cordeliers Research Center, Team Cancer, inflammation and complement, Paris, France; University Paris Descartes, Paris, France; University Pierre et Marie Curie-Paris, Paris, France
| | - Y Velut
- Institut National de La Santé et de La Recherche Médicale (INSERM), UMRS 1138, Cordeliers Research Center, Team Cancer, inflammation and complement, Paris, France; University Paris Descartes, Paris, France; University Pierre et Marie Curie-Paris, Paris, France
| | - A Mansuet-Lupo
- Institut National de La Santé et de La Recherche Médicale (INSERM), UMRS 1138, Cordeliers Research Center, Team Cancer, inflammation and complement, Paris, France; University Paris Descartes, Paris, France; University Pierre et Marie Curie-Paris, Paris, France; Department of Pathology, Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Cochin, Paris, France
| | - L Gibault
- Department of Pathology, Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Paris, France
| | - H Blons
- University Paris Descartes, Paris, France; INSERM UMRS 1147, Paris, France; Department of Biochemistry, APHP, Hôpital Européen Georges Pompidou, Paris, France
| | - L Fournel
- University Paris Descartes, Paris, France; Department of Thoracic Surgery, APHP, Hôpital Cochin, Paris, France; INSERM U1124, Paris, France
| | - A Boni
- Institut National de La Santé et de La Recherche Médicale (INSERM), UMRS 1138, Cordeliers Research Center, Team Cancer, inflammation and complement, Paris, France; University Paris Descartes, Paris, France; University Pierre et Marie Curie-Paris, Paris, France
| | - I Cremer
- Institut National de La Santé et de La Recherche Médicale (INSERM), UMRS 1138, Cordeliers Research Center, Team Cancer, inflammation and complement, Paris, France; University Paris Descartes, Paris, France; University Pierre et Marie Curie-Paris, Paris, France
| | - M Wislez
- Institut National de La Santé et de La Recherche Médicale (INSERM), UMRS 1138, Cordeliers Research Center, Team Cancer, inflammation and complement, Paris, France; University Paris Descartes, Paris, France; Department of Respiratory Medicine, APHP, Hôpital Cochin, Paris, France
| | - V Duchatelle
- Department of Pathology, St Joseph Hospital, Paris, France
| | - J Trédaniel
- University Paris Descartes, Paris, France; INSERM U1124, Paris, France; Department of Oncology, St Joseph Hospital, Paris, France
| | - S A Hammond
- Research and Early Discovery, Oncology Research and Development, AstraZeneca, Gaithersburg, MD, USA
| | - R Herbst
- Research and Early Discovery, Oncology Research and Development, AstraZeneca, Gaithersburg, MD, USA
| | - M Alifano
- Institut National de La Santé et de La Recherche Médicale (INSERM), UMRS 1138, Cordeliers Research Center, Team Cancer, inflammation and complement, Paris, France; University Paris Descartes, Paris, France; University Pierre et Marie Curie-Paris, Paris, France; Department of Thoracic Surgery, APHP, Hôpital Cochin, Paris, France
| | - P Giraud
- University Paris Descartes, Paris, France; APHP, Hôpital Européen Georges Pompidou, Department of Radiotherapy, Paris, France
| | - D Damotte
- Institut National de La Santé et de La Recherche Médicale (INSERM), UMRS 1138, Cordeliers Research Center, Team Cancer, inflammation and complement, Paris, France; University Paris Descartes, Paris, France; University Pierre et Marie Curie-Paris, Paris, France; Department of Pathology, Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Cochin, Paris, France.
| |
Collapse
|
8
|
Bachet JB, Bouché O, Taieb J, Dubreuil O, Garcia ML, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, Bonnetain F, Thirot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Taly V, Blons H, Vernerey D, Laurent-Puig P. RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study. Ann Oncol 2019; 29:1211-1219. [PMID: 29438522 DOI: 10.1093/annonc/mdy061] [Citation(s) in RCA: 108] [Impact Index Per Article: 21.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Background RAS mutations are currently sought for in tumor samples, which takes a median of almost 3 weeks in western European countries. This creates problems in clinical situations that require urgent treatment and for inclusion in therapeutic trials that need RAS status for randomization. Analysis of circulating tumor DNA might help to shorten the time required to determine RAS mutational status before anti-epidermal growth factor receptor antibody therapy for metastatic colorectal cancer. Here we compared plasma with tissue RAS analysis in a large prospective multicenter cohort. Patients and methods Plasma samples were collected prospectively from chemotherapy-naive patients and analyzed centrally by next-generation sequencing (NGS) with the colon lung cancer V2 Ampliseq panel and by methylation digital PCR (WIF1 and NPY genes). Tumoral RAS status was determined locally, in parallel, according to routine practice. For a minimal κ coefficient of 0.7, reflecting acceptable concordance (precision ± 0.07), with an estimated 5% of non-exploitable data, 425 subjects were necessary. Results From July 2015 to December 2016, 425 patients were enrolled. For the 412 patients with available paired plasma and tumor samples, the κ coefficient was 0.71 [95% confidence interval (CI), 0.64-0.77] and accuracy was 85.2% (95% CI, 81.4% to 88.5%). In the 329 patients with detectable ctDNA (at least one mutation or one methylated biomarker), the κ coefficient was 0.89 (95% CI, 0.84-0.94) and accuracy was 94.8% (95% CI, 91.9% to 97.0%). The absence of liver metastases was the main clinical factor associated with inconclusive circulating tumor DNA results [odds ratio = 0.11 (95% CI, 0.06-0.21)]. In patients with liver metastases, accuracy was 93.5% with NGS alone and 97% with NGS plus the methylated biomarkers. Conclusion This prospective trial demonstrates excellent concordance between RAS status in plasma and tumor tissue from patients with colorectal cancer and liver metastases, thus validating plasma testing for routine RAS mutation analysis in these patients. Clinical Trial registration Clinicaltrials.gov, NCT02502656.
Collapse
Affiliation(s)
- J B Bachet
- Sorbonne Universités, UPMC Université, Paris; Université Sorbonne Paris Cité, INSERM UMR-S1147 MEPPOT, CNRS SNC5014, Centre Universitaire des Saints-Pères, Equipe Labellisée Ligue Nationale Contre le Cancer, Paris; Department of Hepato-Gastroenterology, Groupe Hospitalier Pitié Salpêtrière, Paris; AGEO (Association des Gastroentérologues Oncologues), Paris
| | - O Bouché
- AGEO (Association des Gastroentérologues Oncologues), Paris; Department of Hepato-Gastroenterology, Hôpital Robert Debré, Reims
| | - J Taieb
- AGEO (Association des Gastroentérologues Oncologues), Paris; Department of Digestive Oncology, Hôpital Européen Georges Pompidou, Paris
| | - O Dubreuil
- Department of Hepato-Gastroenterology, Groupe Hospitalier Pitié Salpêtrière, Paris; AGEO (Association des Gastroentérologues Oncologues), Paris
| | - M L Garcia
- AGEO (Association des Gastroentérologues Oncologues), Paris; Department of Oncology, Hôpital Saint-Antoine, Paris
| | - A Meurisse
- Department of Methodology and Quality of Life in Oncology, INSERM UMR 1098, Hôpital Universitaire de Besancon, Besancon
| | - C Normand
- Université Sorbonne Paris Cité, INSERM UMR-S1147 MEPPOT, CNRS SNC5014, Centre Universitaire des Saints-Pères, Equipe Labellisée Ligue Nationale Contre le Cancer, Paris
| | - J M Gornet
- AGEO (Association des Gastroentérologues Oncologues), Paris; Department of Gastroenterology, Hôpital Saint-Louis, Paris
| | - P Artru
- AGEO (Association des Gastroentérologues Oncologues), Paris; Department of Gastroenterology, Hôpital Privé Jean Mermoz, Lyon
| | - S Louafi
- AGEO (Association des Gastroentérologues Oncologues), Paris; Department of Gastroenterology, Centre Hospitalier Sud Francilien, Corbeil-Essonnes; Department of Gastroenterology, Groupe Hospitalier Nord Essonne, Longjumeau
| | - F Bonnetain
- Department of Methodology and Quality of Life in Oncology, INSERM UMR 1098, Hôpital Universitaire de Besancon, Besancon
| | - A Thirot-Bidault
- AGEO (Association des Gastroentérologues Oncologues), Paris; Department of Gastroenterology, Hôpital Kremlin Bicêtre, Le Kremlin-Bicêtre
| | - I Baumgaertner
- AGEO (Association des Gastroentérologues Oncologues), Paris; Department of Oncology, Hôpital Henri Mondor, Créteil
| | - R Coriat
- AGEO (Association des Gastroentérologues Oncologues), Paris; Department of Gastroenterology, Hôpital Cochin, Paris
| | - D Tougeron
- AGEO (Association des Gastroentérologues Oncologues), Paris; Depatment of Gastroenterology, Centre Hospitalo-Universitaire de Poitiers, Poitiers
| | - T Lecomte
- AGEO (Association des Gastroentérologues Oncologues), Paris; Department of Gastroenterology, Centre Hospitalo-Universitaire de Tours, Tours
| | - F Mary
- AGEO (Association des Gastroentérologues Oncologues), Paris; Department of Gastroenterology, Hôpital Avicenne, Bobigny
| | - T Aparicio
- AGEO (Association des Gastroentérologues Oncologues), Paris; Department of Gastroenterology, Hôpital Saint-Louis, Paris; Department of Gastroenterology, Hôpital Avicenne, Bobigny
| | - L Marthey
- AGEO (Association des Gastroentérologues Oncologues), Paris; Depatment of Gastroenterology, Hôpital Antoine Béclère, Clamart
| | - V Taly
- Université Sorbonne Paris Cité, INSERM UMR-S1147 MEPPOT, CNRS SNC5014, Centre Universitaire des Saints-Pères, Equipe Labellisée Ligue Nationale Contre le Cancer, Paris
| | - H Blons
- Université Sorbonne Paris Cité, INSERM UMR-S1147 MEPPOT, CNRS SNC5014, Centre Universitaire des Saints-Pères, Equipe Labellisée Ligue Nationale Contre le Cancer, Paris; Department of Biochemistry, Hôpital Européen Georges Pompidou, Paris, France
| | - D Vernerey
- Department of Methodology and Quality of Life in Oncology, INSERM UMR 1098, Hôpital Universitaire de Besancon, Besancon
| | - P Laurent-Puig
- Université Sorbonne Paris Cité, INSERM UMR-S1147 MEPPOT, CNRS SNC5014, Centre Universitaire des Saints-Pères, Equipe Labellisée Ligue Nationale Contre le Cancer, Paris.
| |
Collapse
|
9
|
Moati E, Blons H, Taly V, Garlan F, Shu-Fang WR, Pietrasz D, Didelot A, Garrigou S, Saint A, Pernot S, Taieb J, Laurent-Puig P, Zaanan A. Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz246.100] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
10
|
Thibault C, Audenet F, Borchiellini D, Huillard O, Barthelemy P, Pouessel D, Flechon A, Blons H, Sautès-Fridman C, Sun CM, Verkarre V, Pallet N, Mejean A, Rouabah M, Helali I, Elaidi RT, Oudard S. NEMIO: A randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz249.083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
11
|
Chelabi S, Mignard X, Lacave R, Monnet I, Ollier M, Brosseau S, Theou-Anton N, Massiani M, Doucet L, De Cremoux P, Friard S, Duchemann B, Fabre E, Blons H, Giroux-Leprieur E, Azarian R, Cadranel J, Wislez M. Insertion exon 20 de l’EGFR dans les adénocarcinomes pulmonaires métastatiques : réponse au traitement et survie. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
12
|
Hamard C, Mignard X, Pecuchet N, Mathiot N, Blons H, Laurent-Puig P, Leroy K, Lupo A, Chapron J, Giraud F, Arrondeau J, Goldwasser F, Alifano M, Damotte D, Wislez M. [IHC, FISH, CISH, NGS in non-small cell lung cancer: What changes in the biomarker era?]. Rev Pneumol Clin 2018; 74:327-338. [PMID: 30343945 DOI: 10.1016/j.pneumo.2018.09.013] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Lung cancer is the leading cause of cancer deaths in France, with about 30,000 deaths per year. The overwhelming majority (90 %) are tobacco-related. The prognosis is dark but great therapeutic advances have been made with the development of targeted therapies first and then immunotherapy afterwards. These medications are conditioned to the expression of biomarkers that require specific tools in routine to measure them. We will detail in this chapter several techniques of anatomopathology, cytogenetics and molecular biology necessary for the detection of biomarkers in lung cancers, and their applications in thoracic oncology in 2018.
Collapse
Affiliation(s)
- C Hamard
- Service de pneumologie, hôpital Cochin, Assistance publique-Hôpitaux de Paris, 27, rue du Faubourg-St-Jacques, 75014 Paris, France; Inserm UMRS1138, équipe « cancer, immune control and escape », centre de recherche des Cordeliers, Paris Descartes université, 75006 Paris, France
| | - X Mignard
- GRC n(o) 04, Theranoscan, Sorbonne université, hôpital Tenon, AP-HP, 75020 Paris, France
| | - N Pecuchet
- Inserm UMRS 1147, université Paris Descartes-Sorbonne Paris Cité, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 75015 Paris, France
| | - N Mathiot
- Service de pneumologie, hôpital Cochin, Assistance publique-Hôpitaux de Paris, 27, rue du Faubourg-St-Jacques, 75014 Paris, France
| | - H Blons
- Inserm UMRS 1147, université Paris Descartes-Sorbonne Paris Cité, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 75015 Paris, France
| | - P Laurent-Puig
- Inserm UMRS 1147, université Paris Descartes-Sorbonne Paris Cité, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 75015 Paris, France
| | - K Leroy
- Inserm UMRS1138, équipe « cancer, immune control and escape », centre de recherche des Cordeliers, Paris Descartes université, 75006 Paris, France
| | - A Lupo
- Inserm UMRS1138, équipe « cancer, immune control and escape », centre de recherche des Cordeliers, Paris Descartes université, 75006 Paris, France; Service d'anatomie-pathologique, hôpital Cochin, Assistance publique-Hôpitaux de Paris, 75014 Paris, France
| | - J Chapron
- Service de pneumologie, hôpital Cochin, Assistance publique-Hôpitaux de Paris, 27, rue du Faubourg-St-Jacques, 75014 Paris, France
| | - F Giraud
- Service de pneumologie, hôpital Cochin, Assistance publique-Hôpitaux de Paris, 27, rue du Faubourg-St-Jacques, 75014 Paris, France
| | - J Arrondeau
- Service d'oncologie, hôpital Cochin, Assistance publique-Hôpitaux de Paris, 75014 Paris, France
| | - F Goldwasser
- Inserm UMRS1138, équipe « cancer, immune control and escape », centre de recherche des Cordeliers, Paris Descartes université, 75006 Paris, France; Service d'oncologie, hôpital Cochin, Assistance publique-Hôpitaux de Paris, 75014 Paris, France
| | - M Alifano
- Inserm UMRS1138, équipe « cancer, immune control and escape », centre de recherche des Cordeliers, Paris Descartes université, 75006 Paris, France; Service de chirurgie thoracique, hôpital Cochin, Assistance publique-Hôpitaux de Paris, 75014 Paris, France
| | - D Damotte
- Inserm UMRS1138, équipe « cancer, immune control and escape », centre de recherche des Cordeliers, Paris Descartes université, 75006 Paris, France; Service d'anatomie-pathologique, hôpital Cochin, Assistance publique-Hôpitaux de Paris, 75014 Paris, France
| | - M Wislez
- Service de pneumologie, hôpital Cochin, Assistance publique-Hôpitaux de Paris, 27, rue du Faubourg-St-Jacques, 75014 Paris, France; Inserm UMRS1138, équipe « cancer, immune control and escape », centre de recherche des Cordeliers, Paris Descartes université, 75006 Paris, France.
| |
Collapse
|
13
|
Blons H, Oudart JB, Merlio JP, Hominal S, de Fraipont F, Debieuvre D, Escande F, Audigier Valette C, Bringuier PP, Moreau Fraboulet S, Ouafik L, Moro-Sibilot D, Lemoine A, Langlais A, Missy P, Morin F, Souquet PJ, Barlesi F, Cadranel J, Beau-Faller M. Molecular heterogeneity assessment by NGS in non-small cell lung cancer (NSCLC) harboring EGFR mutations: Results of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy269.123] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Pecuchet N, Touachi R, Ben Lakhdar A, Fallet V, Rabbe N, Blons H, Lemoine A, Antoine M, Tenam S, Laurent-Puig P, Wislez M. Joined analysis of sarcomatoid carcinoma (SC) mutational profiles: Comparison of lung versus head and neck cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy304.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
15
|
Wislez M, Blons H, Domblides C, Barlesi F, Mazieres J, Monnet I, Kiakouama Maleka L, Quantin X, Taillade L, Lena H, Fraisse P, Janicot H, Audigier Valette C, Amour E, Langlais A, Rabbe N, Cadranel J, Laurent puig P, Lavolé A. Circulating tumor DNA (ctDNA) in advanced non-small cell lung cancer (NSCLC) from HIV-infected patients is associated to shorter overall survival (OS): Results from phase II trial (IFCT-1001 CHIVA). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Digan W, Countouris H, Barritault M, Baudoin D, Laurent-Puig P, Blons H, Burgun A, Rance B. An architecture for genomics analysis in a clinical setting using Galaxy and Docker. Gigascience 2018; 6:1-9. [PMID: 29048555 PMCID: PMC5691353 DOI: 10.1093/gigascience/gix099] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2017] [Accepted: 10/09/2017] [Indexed: 12/12/2022] Open
Abstract
Next-generation sequencing is used on a daily basis to perform molecular analysis to determine subtypes of disease (e.g., in cancer) and to assist in the selection of the optimal treatment. Clinical bioinformatics handles the manipulation of the data generated by the sequencer, from the generation to the analysis and interpretation. Reproducibility and traceability are crucial issues in a clinical setting. We have designed an approach based on Docker container technology and Galaxy, the popular bioinformatics analysis support open-source software. Our solution simplifies the deployment of a small-size analytical platform and simplifies the process for the clinician. From the technical point of view, the tools embedded in the platform are isolated and versioned through Docker images. Along the Galaxy platform, we also introduce the AnalysisManager, a solution that allows single-click analysis for biologists and leverages standardized bioinformatics application programming interfaces. We added a Shiny/R interactive environment to ease the visualization of the outputs. The platform relies on containers and ensures the data traceability by recording analytical actions and by associating inputs and outputs of the tools to EDAM ontology through ReGaTe. The source code is freely available on Github at https://github.com/CARPEM/GalaxyDocker.
Collapse
Affiliation(s)
- W Digan
- University Hospital Georges Pompidou, HEGP, Department of Medical Informatics, AP-HP, INSERM, Centre de Recherche des Cordeliers, UMRS 1138, Université Sorbonne Paris Cité, University Paris-Descartes, Paris, France
| | - H Countouris
- University Hospital Georges Pompidou, HEGP, Department of Medical Informatics, AP-HP, INSERM, Centre de Recherche des Cordeliers, UMRS 1138, Université Sorbonne Paris Cité, University Paris-Descartes, Paris, France
| | - M Barritault
- University Hospital Georges Pompidou, HEGP, Department of Biochemistry, Pharmacogenetics and Molecular Oncology, AP-HP, Paris, France, University Paris-Descartes
| | - D Baudoin
- University Hospital Georges Pompidou, HEGP, Department of Medical Informatics, AP-HP, INSERM, Centre de Recherche des Cordeliers, UMRS 1138, Université Sorbonne Paris Cité, University Paris-Descartes, Paris, France
| | - P Laurent-Puig
- INSERM UMR-S1147, CNRS SNC 5014, Université Sorbonne Paris Cité, Paris, France
| | - H Blons
- University Hospital Georges Pompidou, HEGP, Department of Biochemistry, Pharmacogenetics and Molecular Oncology, AP-HP, Paris, France, University Paris-Descartes.,INSERM UMR-S1147, CNRS SNC 5014, Université Sorbonne Paris Cité, Paris, France
| | - A Burgun
- University Hospital Georges Pompidou, HEGP, Department of Medical Informatics, AP-HP, INSERM, Centre de Recherche des Cordeliers, UMRS 1138, Université Sorbonne Paris Cité, University Paris-Descartes, Paris, France
| | - B Rance
- University Hospital Georges Pompidou, HEGP, Department of Medical Informatics, AP-HP, INSERM, Centre de Recherche des Cordeliers, UMRS 1138, Université Sorbonne Paris Cité, University Paris-Descartes, Paris, France
| |
Collapse
|
17
|
Leduc C, Pencreach E, Merlio J, Bringuier P, De Fraipont F, Escande F, Lemoine A, Ouafik L, Blons H, Denis M, Hofman P, Lacave R, Melaabi S, Langlais A, Missy P, Morin F, Barlesi F, Moro-Sibilot D, Cadranel J, Beau-Faller M. Détection de la mutation T790 M par PCR digitale dans une population de cancers bronchiques non à petites cellules (CBNPC) mutés EGFR, avant le traitement par ITK-EGFR : résultats d’une étude ancillaire à l’étude IFCT Biomarqueurs – France. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
18
|
Leduc C, Merlio JP, Besse B, Blons H, Debieuvre D, Bringuier PP, Monnet I, Rouquette I, Fraboulet-Moreau S, Lemoine A, Pouessel D, Mosser J, Vaylet F, Langlais A, Missy P, Morin F, Moro-Sibilot D, Cadranel J, Barlesi F, Beau-Faller M. Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. Ann Oncol 2017; 28:2715-2724. [PMID: 28945865 DOI: 10.1093/annonc/mdx404] [Citation(s) in RCA: 59] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND EGFR mutations cause inconsistent response to EGFR tyrosine-kinase inhibitors (TKI). To better understand these features, we reviewed all cases of EGFR-mutated non-small-cell lung cancer collected in the Biomarkers France database. PATIENTS AND METHODS Of 17 664 patients, 1837 (11%) with EGFR-mutated non-small-cell lung cancer were retrospectively analyzed for clinical and molecular characteristics. Results were correlated with survival and treatment response for the 848 stage IV patients. RESULTS EGFR exon 18, 19, 20 and 21 mutations were found in 102 (5.5%), 931 (51%), 102 (5.5%) and 702 (38%) patients, respectively. Over 50% of exon 18 and 20 mutated patients were smokers. The median follow-up was 51.7 months. EGFR mutation type was prognostic of overall survival (OS) versus wild-type {exon 19: hazard ratio (HR)=0.51 [95% confidence interval (CI): 0.41-0.64], P < 0.0001; exon 21: HR = 0.76 (95% CI: 0.61-0.95), P = 0.002; exon 20: HR = 1.56 (95% CI: 1.02-2.38), P = 0.004}. EGFR mutation type was prognostic of progression-free survival versus wild-type [exon 19: HR = 0.62 (95% CI: 0.49-0.78), P < 0.0001; exon 20: HR = 1.46 (95% CI: 0.96-2.21), P = 0.07]. First-line treatment choice did not influence OS in multivariate analysis. First-line TKI predicted improved progression-free survival versus chemotherapy [HR = 0.67 (95% CI: 0.53-0.85), P = 0.001]. OS was longer for del19 versus L858R, which was associated with better OS compared with other exon 21 mutations, including L861Q. TKI improved survival in patients with exon 18 mutations, while chemotherapy was more beneficial for exon 20-mutated patients. CONCLUSION EGFR mutation type can inform the most appropriate treatment. Therapeutic schedule had no impact on OS in our study, although TKI should be prescribed in first-line considering the risk of missing the opportunity to use this treatment.
Collapse
Affiliation(s)
- C Leduc
- Department of Chest, Centre Hospitalier Universitaire de Strasbourg, Nouvel Hôpital Civil, Strasbourg
| | - J P Merlio
- Department of Biology and Pathology, Centre Hospitalier Universitaire de Bordeaux, Pessac;; Histology and Molecular Pathology of Tumors, Université de Bordeaux, Bordeaux
| | - B Besse
- Medicine Department, Gustave Roussy Cancer Campus, Villejuif
| | - H Blons
- INSERM UMR-S1147, Université Sorbonne Paris Cité, Paris;; Department of Biochemistry, Pharmacogenetics and Molecular Oncology, Hôpital Européen Georges Pompidou (HEGP), Assistance Publique - Hôpitaux de Paris, Paris
| | - D Debieuvre
- Department of Chest, Hôpital Emile Muller - GHRMSA, Mulhouse
| | - P P Bringuier
- Department of Biology and Pathology, Hospices Civils de Lyon, Lyon;; Université Claude Bernard Lyon 1, Lyon
| | - I Monnet
- Pneumology Department, Centre Hospitalier Intercommunal de Créteil, Créteil
| | - I Rouquette
- Pathology Department, Centre Hospitalier Universitaire de Toulouse Institut Universitaire du Cancer de Toulouse, Oncopôle, Toulouse
| | | | - A Lemoine
- Biochemistry and Oncogenetic Department, Oncomolpath, Assistance Publique - Hôpitaux de Paris, Paris;; Groupe Hospitalier des Hôpitaux Universitaires Paris-Sud, Université Paris 11, Villejuif
| | - D Pouessel
- Medical Oncology Department, Hôpital Saint Louis, Assistance Publique - Hôpitaux de Paris, Paris
| | - J Mosser
- Department of Molecular Genetics and Genomics - Medical Genomics, Centre Hospitalier Universitaire de Rennes, Rennes
| | - F Vaylet
- Department of Chest, Hôpital d'Instruction des Armées Percy, Clamart
| | - A Langlais
- Department of Biostatistics, Francophone de Cancérologie Thoracique, Paris
| | - P Missy
- Clinical Research Unit, Intergroupe Francophone de Cancérologie Thoracique, Paris
| | - F Morin
- Clinical Research Unit, Intergroupe Francophone de Cancérologie Thoracique, Paris
| | - D Moro-Sibilot
- Thoracic Oncology Unit, Centre Hospitalier Universitaire Grenoble-Alpes, Clinique de Pneumologie, Grenoble
| | - J Cadranel
- Department of Chest, Assistance Publique - Hôpitaux de Paris, Hôpital Tenon, Paris;; Sorbonne Université, UPMC Univ Paris 06, GRC n-04, Theranoscan, Paris
| | - F Barlesi
- Assistance Publique - Hôpitaux de Marseille, Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Centre d'Investigation Clinique, Marseille
| | - M Beau-Faller
- Laboratory of Biochemistry and Molecular Biology, Centre Hospitalier Universitaire de Strasbourg, Hôpital de Hautepierre, Strasbourg;; EA3430 "Progression Tumorale et Microenvironnement, Approches Translationnelles et Épidémiologie," Strasbourg, France.
| |
Collapse
|
19
|
Leduc C, Pencreach E, Merlio JP, Bringuier PP, de Fraipont F, Escande F, Lemoine A, L'Houcine O, Blons H, Denis M, Hofman P, Lacave R, Melaabi S, Langlais A, missy P, Morin F, Barlesi F, Moro-Sibilot D, Cadranel J, Beau-Faller M. Ultrasensitive detection of EGFR T790M mutation by droplet digital PCR (ddPCR) in TKI naïve non-small cell lung cancer (NSCLC) harboring EGFR mutation: Results of the nationwide program Biomarkers France of the French Cooperative Thoracic Intergroup (IFCT). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx363.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Leduc C, Blons H, Besse B, Merlio J, Debieuvre D, Lemoine A, Monnet I, Pouessel D, Bringuier P, Poudenx M, Rouquette I, Vaylet F, Morin F, Langlais A, Quoix E, Zalcman G, Moro-Sibilot D, Cadranel J, Beau-Faller M, Barlesi F. Caractéristiques cliniques et moléculaires des patients atteints d’un cancer bronchique non à petites cellules (CBNPC) avec mutation de l’EGFR : étude ancillaire de l’étude IFCT biomarqueurs France. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
21
|
Leduc C, Blons H, Besse B, Merlio JP, Debieuvre D, Lemoine A, Monnet I, Pouessel D, Bringuier P, Poudenx M, Rouquette I, Vaylet F, Morin F, Langlais A, Quoix E, Zalcman G, Moro-Sibilot D, Cadranel J, Beau-Faller M, Barlesi F. Clinical and biological characteristics of non-small cell lung cancer (NSCLC) harbouring EGFR mutation: Results of the nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.02] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Zaanan A, Garlan F, Didelot A, Perkins G, Siauve N, Blons H, Taieb J, Taly V, Laurent-Puig P. Prognostic value of circulating tumor DNA in advanced colorectal cancer patients: Quantification of hypermethylated or mutant sequences using picoliter droplet digital PC. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.78] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
23
|
Perkins G, Fabre E, Fallet V, Blons H, Pecuchet N, Gounant V, Gibault L, Michel-Jeljeli E, Antoine M, Roux E, Wislez M, Le Corre D, Leroy K, Lacave R, Taieb J, Cadranel J, Laurent-Puig P. Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw363.44] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
24
|
Legras A, Roussel H, Gibault L, Pricopi C, Fabre E, Laurent-Puig P, Blons H, Pimpec-Barthes FL. P-242TUMOUR HETEROGENEITY OF PRIMITIVE LUNG CANCER AND METASTATIC LYMPH NODES. Interact Cardiovasc Thorac Surg 2016. [DOI: 10.1093/icvts/ivw260.239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
Pecuchet N, Laurent-Puig P, Mansuet-Luppo A, Legras A, Alifano M, Pallier K, Didelot A, Gibault L, Danel C, Just P, Le Pimpec-Barthes F, Damotte D, Fabre E, Blons H. 208 Different prognostic impact of STK11 mutations in Non-Small-Cell Lung Cancer (NSCLC) illustrates the switch from a tumor suppressor to an oncogene. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30096-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
26
|
Legras A, Pecuchet N, Tallet A, Guyard A, Mansuet-Lupo A, Prieur EGL, Giraudet V, Gibault L, Damotte D, Julie C, Alifano M, Pimpec-Barthes FL, Laurent-Puig P, Fabre E, Blons H. 468 Validity of next generation sequencing in routine care for non-small cell lung cancer diagnosis. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30302-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
27
|
Blons H, Emile JF, Le Malicot K, Julié C, Zaanan A, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Nørgård-Petersen L, Van Cutsem E, Lepage C, Zawadi MA, Salazar R, Laurent-Puig P, Taieb J. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. Ann Oncol 2014; 25:2378-2385. [PMID: 25294886 DOI: 10.1093/annonc/mdu464] [Citation(s) in RCA: 78] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND The prognostic value of KRAS mutations in colon adenocarcinoma is controversial. We examined this question as an ancillary study of the PETACC8 phase III trial. PATIENTS AND METHODS We analyzed the prognostic impact of KRAS exon 2 mutations in stage III colon cancer patients (n = 1657) receiving adjuvant FOLFOX ± cetuximab therapy included in the PETACC8 trial. Patients with BRAF-mutated cancers were excluded and, as no difference was found for time to recurrence (TTR) and disease-free survival (DFS) between treatment arms, both were pooled for analysis. Associations with TTR and DFS were analyzed using a Cox proportional hazards model. RESULTS KRAS mutations were found in 638 of 1657 tumors and linked to shorter TTR (P < 0.001). However, when specific mutations were compared with wild-type, codon 12 mutations [hazard ratio (HR) 1.67, 95% confidence interval (CI) 1.35-2.04; P < 0.001] but not codon 13 (HR 1.23, 95% CI 0.85-1.79; P = 0.26) were significantly associated with shorter TTR, independently of other covariates. The interaction test showed that, regarding tumor location (distal versus proximal), KRAS genotype affects differently on recurrence (P = 0.02) and DFS (P = 0.042). Subgroup analysis showed that KRAS only affected TTR and DFS in distal tumors (n = 1043; 692 wild type; 351 mutated), with an increased risk of relapse (HR 1.96, 95% CI 1.51-2.56; P < 0.0001) for KRAS codon 12 mutations and a borderline significance for codon 13 mutations (HR 1.59, 95% CI 1.00-2.56; P = 0.051). CONCLUSION KRAS exon 2 mutations are independent predictors of shorter TTR in patients with resected stage III distal colon cancers receiving adjuvant therapy. Future clinical trials in the adjuvant setting should consider both the tumor location and KRAS mutations as important stratification factors. CLINICAL TRIAL NUMBER This is an ancillary study of the PETACC8 trial: EUDRACT 2005-003463-23.
Collapse
Affiliation(s)
- H Blons
- UMR-S1147, INSERM, Paris; Paris Descartes University, Paris; APHP Department of Biology, Georges Pompidou Hospital, Paris
| | - J F Emile
- Department of Pathology, APHP Ambroise Paré Hospital, Boulogne-Billancourt; Paris-Ouest University, Versailles Saint-Quentin
| | - K Le Malicot
- Department of Statistics, Fédération Francophone de Cancérologie Digestive, Dijon
| | - C Julié
- Department of Pathology, APHP Ambroise Paré Hospital, Boulogne-Billancourt
| | - A Zaanan
- APHP Department of Hepatogastroenterology and GI Oncology, Georges Pompidou Hospital, Paris, France
| | - J Tabernero
- Department of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain
| | - E Mini
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | - G Folprecht
- 1st Medical Department, University Hospital Carl Gustav Carus, Dresden, Germany
| | - J L Van Laethem
- Deptartment of Gastroenterology, Erasme University Hospital, Brussels, Belgium
| | - J Thaler
- Department of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria
| | - J Bridgewater
- UCL Cancer Institute, University College London, London, UK
| | | | - E Van Cutsem
- Department of Digestive Oncology, University Hospitals and KULeuven, Leuven, Belgium
| | - C Lepage
- Department of Hepato-Gastroenterology, Dijon University Hospital and INSERM U 866, Dijon
| | - M A Zawadi
- GI Oncology, Les Oudairies Hospital, La Roche sur Yon, France
| | - R Salazar
- Catalan Institute of Oncology (IDIBELL), Barcelona, Spain
| | - P Laurent-Puig
- UMR-S1147, INSERM, Paris; Paris Descartes University, Paris; APHP Department of Biology, Georges Pompidou Hospital, Paris
| | - J Taieb
- APHP Department of Hepatogastroenterology and GI Oncology, Georges Pompidou Hospital, Paris, France; Paris Descartes University, Paris.
| |
Collapse
|
28
|
Beau-Faller M, Texier M, Blons H, Richard N, Escande F, Bièche I, Lizard S, De Fraipont F, Morin F, Zalcman G, Pignon J, Cadranel J. Ermetic-2 Project : Impact of Systematic Egfr and Kras Mutation Evaluation By Alternative Testing Methods on Progression-Free (Pfs) and Overall Survival (Os) in Patients with Advanced Non–Small-Cell Lung Cancer (Nsclc) Treated By Erlotinib (E) in the Ifct Ermetic Cohort. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.88] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Blons H, Emile J, Le Malicot K, Zaanan A, Tabernero J, Mini E, Folprecht G, van Laethem J, Thaler J, Bridgewater J, Petersen L, Van Cutsem E, Lepage C, Salazar R, Laurent-Puig P, Taieb J. Prognostic Value of Kras Mutations in Stage III Colon Cancer: Post-Hoc Analyses of the Petacc8 Phase III Trial. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu333.74] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Pecuchet N, Didelot A, Zonta E, Lours C, Gibault L, Rice N, Laurent-Puig P, Fabre E, Taly V, Blons H. Plasmatic Tumor Dna Assessments Predict Clinical Outcome in Egfr-Mutated Non-Small Cell Lung Cancer Patients Treated By Egfr Inhibitors. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.59] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Taieb J, Emile J, Le Malicot K, Zaanan A, Tabernero J, Mini E, Folprecht G, Van Laethem J, Thaler J, Bridgewater J, Petersen L, Van Cutsem E, Lepage C, Salazar R, Laurent-Puig P, Blons H. Prognostic Value of KRAS Mutations in Stage III Colon Cancer: Post-Hoc Analyses of the Petacc8 Phase III Trial. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu193.24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
32
|
Gibault L, Cazes A, Narjoz C, Blons H. [Molecular profiling of non-small cell lung cancer]. Rev Pneumol Clin 2014; 70:47-62. [PMID: 24566035 DOI: 10.1016/j.pneumo.2013.11.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/25/2013] [Revised: 10/24/2013] [Accepted: 11/01/2013] [Indexed: 06/03/2023]
Abstract
The management of locally advanced and metastatic non-small cell lung cancer has been revolutionized thanks to recent progress in pathology and molecular biology. The first molecular subgroup is defined by activating mutations of the epidermal growth factor receptor (EGFR), and a dramatic response to specific tyrosine kinase inhibitors. Since then, multiple genetic alterations (KRAS, HER2, BRAF, PIK3CA, ALK, ROS, RET…) have been identified as potential target of novel therapies, and molecular profiling has become common practice. This review focus on the molecular alterations associated with non-small cell lung cancer, including molecular profiling and response to targeted therapies.
Collapse
Affiliation(s)
- L Gibault
- Service de pathologie, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 20, rue Leblanc, 75015 Paris, France
| | - A Cazes
- Service de pathologie, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 20, rue Leblanc, 75015 Paris, France; Université Paris Descartes, 12, rue de l'École-de-Médecine, 75006 Paris, France
| | - C Narjoz
- Service de biochimie, UF de pharmacogénétique et oncologie moléculaire, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 20, rue Leblanc, 75015 Paris, France
| | - H Blons
- Université Paris Descartes, 12, rue de l'École-de-Médecine, 75006 Paris, France; Service de biochimie, UF de pharmacogénétique et oncologie moléculaire, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 20, rue Leblanc, 75015 Paris, France; UMR-S775, Inserm, centre universitaire des Saints-Pères, 46, rue des Saints-Pères, 75006 Paris, France.
| |
Collapse
|
33
|
Barlesi F, Blons H, Beau-Faller M, Rouquette I, Ouafik L, Mosser J, Merlio J, Bringuier P, Jonveaux P, Le Marechal C, Denis M, Penault-Llorca F, Debieuvre D, Soria J, Cadranel J, Mazieres J, Missy P, Morin F, Nowak F, Zalcman G. Biomarqueurs France : résultats de l’analyse en routine de EGFR, HER2, KRAS, BRAF, PI3K, et ALK sur 10 000 patients (pts) atteints de cancer bronchique non à petites cellules (CBNPC). Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2013.10.041] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
34
|
Beau-Faller M, Prim N, Ruppert AM, Nanni-Metéllus I, Lacave R, Lacroix L, Escande F, Lizard S, Pretet JL, Rouquette I, de Crémoux P, Solassol J, de Fraipont F, Bièche I, Cayre A, Favre-Guillevin E, Tomasini P, Wislez M, Besse B, Legrain M, Voegeli AC, Baudrin L, Morin F, Zalcman G, Quoix E, Blons H, Cadranel J. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol 2013; 25:126-31. [PMID: 24285021 DOI: 10.1093/annonc/mdt418] [Citation(s) in RCA: 231] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND There is scarce data available about epidermal growth factor receptor (EGFR) mutations other than common exon 19 deletions and exon 21 (L858R) mutations. PATIENTS AND METHODS EGFR exon 18 and/or exon 20 mutations were collected from 10 117 non-small-cell lung cancer (NSCLC) samples analysed at 15 French National Cancer Institute (INCa)-platforms of the ERMETIC-IFCT network. RESULTS Between 2008 and 2011, 1047 (10%) samples were EGFR-mutated, 102 (10%) with rare mutations: 41 (4%) in exon 18, 49 (5%) in exon 20, and 12 (1%) with other EGFR mutations. Exon 20 mutations were related to never-smoker status, when compared with exon 18 mutations (P < 0.001). Median overall survival (OS) of metastatic disease was 21 months [95% confidence interval (CI) 12-24], worse in smokers than in non-smoker patients with exon 20 mutations (12 versus 21 months; hazard ratio [HR] for death 0.27, 95% CI 0.08-0.87, P = 0.03). Under EGFR-tyrosine kinase inhibitors (TKIs), median OS was 14 months (95% CI 6-21); disease control rate was better for complex mutations (6 of 7, 86%) than for single mutations (16 of 40, 40%) (P = 0.03). CONCLUSIONS Rare EGFR-mutated NSCLCs are heterogeneous, with resistance of distal exon 20 insertions and better sensitivity of exon 18 or complex mutations to EGFR-TKIs, probably requiring individual assessment.
Collapse
Affiliation(s)
- M Beau-Faller
- Department of Biochemistry and Molecular Biology, Strasbourg University Hospital, Strasbourg
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Cros J, Sbidian E, Hans S, Roussel H, Scotte F, Tartour E, Brasnu D, Laurent-Puig P, Bruneval P, Blons H, Badoual C. Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours. Ann Oncol 2013; 24:2624-2629. [PMID: 23933559 DOI: 10.1093/annonc/mdt338] [Citation(s) in RCA: 62] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Malignant tumours of the salivary glands (MSGT) are rare and pleomorphic entities. Patients with advanced disease may benefit from targeted therapy; however, specific targets for optimising and personalising treatments are yet to be identified. DESIGN Immunohistochemistry for C-KIT, EGFR, HER2, MUC1, phospho-mTOR, androgen/estrogens/progesterone receptors and Ki67 was carried out and evaluated in terms of progression-free and overall survival. High throughput molecular screening of key oncogenes was done in 107 patients using routine diagnostic methods and Sequenom technology. RESULTS Several therapy leads were identified, including high levels of HER2 and androgen receptors in salivary duct carcinomas, C-KIT in myoepithelial carcinomas and EGFR in mucoepidermoid carcinomas. Recurrent mutations involving downstream elements of the EGFR pathway were found in HRAS, notably in tumours with a myoepithelial component, and in other key oncogenes (KRAS/NRAS/PI3KCA/BRAF/MAP2K). On the other hand, <1% of samples had EGFR or HER2 mutations. CONCLUSION Several tumour subtypes overexpressed targets of directed therapies suggesting potential therapy leads. Genotyping results suggest activation downstream of EGFR in 18 of the 107 samples that could be associated with low efficacy of EGFR inhibitors. Other molecules, such as PI3K/MEK or mTOR inhibitors, may have anti-tumour activity in this subgroup. The high mutation rate in HRAS highlights a novel key oncogenic event in MSGT.
Collapse
Affiliation(s)
- J Cros
- Department of Pathology, G. Pompidou European Hospital APHP-Université Paris Descartes, Paris
| | - E Sbidian
- Department of Public Health, University Paris Est Créteil-EA4393, Creteil
| | - S Hans
- Departments of Head and Neck Surgery
| | - H Roussel
- Department of Pathology, G. Pompidou European Hospital APHP-Université Paris Descartes, Paris
| | - F Scotte
- Oncology, G. Pompidou European Hospital-Université Paris Descartes, Paris
| | - E Tartour
- INSERM U970 Paris-Centre de recherche Cardiovasculaire Team 10, Paris
| | - D Brasnu
- Departments of Head and Neck Surgery
| | - P Laurent-Puig
- Department of Biochemistry and Molecular Oncology, G. Pompidou European Hospital-Université Paris Descartes, Inserm Unité Mixte de Recherche-S775, Paris, France
| | - P Bruneval
- Department of Pathology, G. Pompidou European Hospital APHP-Université Paris Descartes, Paris
| | - H Blons
- Department of Biochemistry and Molecular Oncology, G. Pompidou European Hospital-Université Paris Descartes, Inserm Unité Mixte de Recherche-S775, Paris, France
| | - C Badoual
- Department of Pathology, G. Pompidou European Hospital APHP-Université Paris Descartes, Paris; INSERM U970 Paris-Centre de recherche Cardiovasculaire Team 10, Paris.
| |
Collapse
|
36
|
André T, Blons H, Mabro M, Chibaudel B, Bachet JB, Tournigand C, Bennamoun M, Artru P, Nguyen S, Ebenezer C, Aissat N, Cayre A, Penault-Llorca F, Laurent-Puig P, de Gramont A. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. Ann Oncol 2013; 24:412-419. [PMID: 23041588 DOI: 10.1093/annonc/mds465] [Citation(s) in RCA: 69] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND The purpose of this study was to evaluate the combination of panitumumab and irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy (oxaliplatin, fluoropyrimidines-irinotecan and bevacizumab). PATIENTS AND METHODS KRAS status was first determined locally but subsequent validation of KRAS status and additional screenings (rare KRAS, NRAS, BRAF mutations and EGFR copy number) were centrally assessed. Patients received panitumumab (6 mg/kg) and irinotecan (180 mg/m²) every 2 weeks. RESULTS Sixty-five eligible patients were analyzed. The objective response rate (ORR) was 29.2% [95% confidence interval (95% CI) 18.2-40.3]. Median progression-free and overall survivals were 5.5 and 9.7 months, respectively. Most frequent grade 3/4 toxic effects were skin 32.3%, diarrhea 15.4% and neutropenia 12.3%. Tissue samples were available for 60 patients. For the confirmed KRAS wild-type population codon 12 or 13 mutation (n = 54), ORR was 35.2% (95% CI 22.4.1-47.9). Thirteen patients had a NRAS, a BRAF or a rare KRAS mutation, and no tumor response was observed in this subgroup when compared with 46.3% (95% CI 31.1-61.6) ORR in the subgroup of 41 patients with no identified mutation. CONCLUSION Panitumumab and irinotecan is an active third-line regimen in a well-defined population based on biomarkers. ClinicalTrials.gov Identifier NCT00655499.
Collapse
Affiliation(s)
- T André
- Department of medical Oncology, Hôpital Saint-Antoine, Université Paris VI, Paris; Department of Clinical Research, GERCOR, Paris.
| | - H Blons
- Université Paris Sorbonne Cité; Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) - S775 Molecular Basis of Xenobiotics Response; Assistance Publique Hôpitaux de Paris Hôpital Européen Georges Pompidou, Paris
| | - M Mabro
- Department of Clinical Research, GERCOR, Paris; Department of medical Oncology,Hôpital Foch, Suresnes, France
| | - B Chibaudel
- Department of medical Oncology, Hôpital Saint-Antoine, Université Paris VI, Paris; Department of Clinical Research, GERCOR, Paris
| | - J-B Bachet
- Department of Clinical Research, GERCOR, Paris; Department of Hepato-Gastro-Enterology, Hôpital La Pitié Salpetrière, Paris
| | - C Tournigand
- Department of medical Oncology, Hôpital Saint-Antoine, Université Paris VI, Paris; Department of Clinical Research, GERCOR, Paris
| | - M Bennamoun
- Department of Clinical Research, GERCOR, Paris; Department of medical Oncology, Institut Mutualiste Montsouris, Paris, France
| | - P Artru
- Department of Clinical Research, GERCOR, Paris; Departement of Hepato-Gastro-Enterology, Hôpital Privé Jean Mermoz, Lyon, France
| | - S Nguyen
- Department of medical Oncology, Centre Hospitalier de Beauvais, Beauvais, France
| | - C Ebenezer
- Department of medical Oncology, Hôpital Saint-Antoine, Université Paris VI, Paris
| | - N Aissat
- Department of Clinical Research, GERCOR, Paris
| | - A Cayre
- Biology and Tumor Pathology Department, Centre Jean-Perrin, Université d'Auvergne Equipe Associée EA4233 Centre Hospitalier Universitaire (CHU) Clermont-Ferrand
| | - F Penault-Llorca
- Biology and Tumor Pathology Department, Centre Jean-Perrin, Université d'Auvergne Equipe Associée EA4233 Centre Hospitalier Universitaire (CHU) Clermont-Ferrand
| | - P Laurent-Puig
- Université Paris Sorbonne Cité; Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) - S775 Molecular Basis of Xenobiotics Response; Assistance Publique Hôpitaux de Paris Hôpital Européen Georges Pompidou, Paris
| | - A de Gramont
- Department of medical Oncology, Hôpital Saint-Antoine, Université Paris VI, Paris; Department of Clinical Research, GERCOR, Paris
| |
Collapse
|
37
|
Hélias-Rodzewicz Z, Colomba E, Von Diemling A, Marin C, Terrones N, Pechaud D, Surel S, Côté JF, Peschaud F, Capper D, Blons H, Zimmermann U, Clerici T, Saiag P, Emile JF. Détection des mutations BRAFV600 dans les mélanomes : la comparaison de quatre techniques est en faveur d’une stratégie de d’immuno-histochimie éventuellement suivie d’un pyroséquensage. Ann Pathol 2012. [DOI: 10.1016/j.annpat.2012.09.114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
38
|
Lupo A, Blons H, Alifano M, Charpentier MC, Ducruit V, Devez F, Bain S, Marmey B, Leduc M, Zouiti F, Régnard JF, Laurent-Puig P, Molina TJ, Damotte D. Réarrangement du locus ALK dans les adénocarcinomes pulmonaires : corrélation immunohistochimique et FISH. Ann Pathol 2012. [DOI: 10.1016/j.annpat.2012.09.140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
39
|
Fabre E, Pécuchet N, Laurent-Puig P, Pallier K, Le Pimpec-Barthes F, Riquet M, Cazes A, Blons H. Predictive Value of LKB1 in Patients with Resected Non Small Cell Lung Cancer. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32743-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
40
|
|
41
|
Rico A, Didelot A, Rosella P, Blons H, Laurent-Puig P. 578 Detection of Hot Spot Mutations by Semi-conductor Sequencing of DNA Extracted From Formalin Fixed Paraffin Embedded (FFPE) Colon Rectal Cancer Samples. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71236-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
42
|
Cros J, Blons H, Bruneval P, Brasnu D, Laurent-Puig P, Badoual C. Altérations moléculaires de la voie de l’EGFR dans les tumeurs malignes des glandes salivaires. Ann Pathol 2011. [DOI: 10.1016/j.annpat.2011.09.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
43
|
Andre T, Chibaudel B, Mabro M, Bennamoun M, Artru P, Bachet J, Hadengue A, Blons H, Laurent-Puig P, de Gramont A. 6144 POSTER Phase II Study of Panitumumab With Irinotecan for Patients With KRas Wild-type Metastatic Colorectal Cancer (MCRC) Refractory to Standard Chemotherapy – a GERCor Study. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71789-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
44
|
Chibaudel B, Tournigand C, Mabro M, Bennamoun M, Artru P, Nguyen S, Bachet J, Aissat N, Blons H, Laurent-Puig P, De Gramont A, Andre T. Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: A GERCOR study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3573] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Le Garff-Tavernier M, Blons H, Nguyen-Khac F, Pannetier M, Brissard M, Gueguen S, Jacob F, Ysebaert L, Susin SA, Merle-Béral H. Functional assessment of p53 in chronic lymphocytic leukemia. Blood Cancer J 2011; 1:e5. [PMID: 22829111 PMCID: PMC3255272 DOI: 10.1038/bcj.2011.3] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
|
46
|
Blons H, Le Corre D, Pagès J, Tan R, Joiner M, Petraroli R, Chen C, Puig P. 181 Accuracy of castPCR-based KRAS testing on paraffin embedded tissues. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)70988-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
47
|
Abstract
The anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies cetuximab and panitumumab have been demonstrated to be new therapeutic options for metastatic colorectal cancer (mCRC). Oncogenic activation of intracellular signalling pathways downstream of EGFR has a major role in colorectal carcinogenesis but has also been reported to be an important mechanism of resistance to anti-EGFR antibodies. Among the activating mutations found in colorectal cancers, tumour KRAS mutations, which are found in approximately 40% of the cases, have been widely demonstrated as a major predictive marker of resistance to cetuximab or panitumumab, therefore, opening the way to individualized treatment for patients with mCRC. Other oncogenic mutations, such as BRAF or PIK3CA mutations or loss of PTEN expression, may also be additional interesting predictive markers of response to anti-EGFR monoclonal antibodies but required further evaluation before being incorporated in clinical practice. The identification of these molecular markers involved in the resistance of anti-EGFR antibodies will allow the development of new therapies that should target 'escape mechanisms' used by tumours to circumvent a pathway that has been pharmacologically blocked by anti-EGFR.
Collapse
Affiliation(s)
- A Lièvre
- INSERM UMR-S 775 Molecular Basis of Response to Xenobiotics, Paris, France
| | | | | |
Collapse
|
48
|
Lièvre A, Blons H, Houllier AM, Laccourreye O, Brasnu D, Beaune P, Laurent-Puig P. Clinicopathological significance of mitochondrial D-Loop mutations in head and neck carcinoma. Br J Cancer 2006; 94:692-7. [PMID: 16495928 PMCID: PMC2361200 DOI: 10.1038/sj.bjc.6602993] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Mitochondrial DNA mutations have been reported in several types of tumours, including head and neck squamous cell carcinoma (HNSCC). The noncoding region of the Displacement-Loop (D-Loop) has emerged as a mutational hotspot and we recently found that they were associated with prognosis and response to 5 fluorouracil (5FU) in colon cancers. In order to evaluate the frequence of D-Loop mutations in a large series of HNSCC and establish correlations with clinicopathologic parameters, we sequenced the D-Loop of 109 HNSCC before a treatment by neoadjuvant 5FU-cisplatin-based chemotherapy and surgery. Then, we correlated these mutations with prognosis and response to chemotherapy. A D-Loop mutation was identified in 21% of the tumors, the majority of them were located in a C-tract (D310). The prevalence of D310 mutations increased significantly with the number of cytosines in the matched normal tissue sequence (P=0.02). Hypopharyngeal cancer was significantly more frequent (P=0.03) and tobacco consumption more important (P=0.01) in the group of patients with D-Loop mutation. The presence of D-Loop mutation was not associated with prognosis or with response to neoadjuvant chemotherapy. These results suggest that D-Loop mutations should be considered as a cancer biomarker that may be useful for the early detection of HNSCC in individuals at risk of this cancer.
Collapse
Affiliation(s)
- A Lièvre
- INSERM, U490, Université René Descartes, Paris F-75006, France
| | - H Blons
- INSERM, U490, Université René Descartes, Paris F-75006, France
- Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, pôle biologie, Paris F-75015, France
| | - A M Houllier
- INSERM, U490, Université René Descartes, Paris F-75006, France
| | - O Laccourreye
- Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, service d'Oto-Rhino-Laryngologie et de Chirurgie cervico-faciale, Paris F-75015, France
| | - D Brasnu
- Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, service d'Oto-Rhino-Laryngologie et de Chirurgie cervico-faciale, Paris F-75015, France
| | - P Beaune
- INSERM, U490, Université René Descartes, Paris F-75006, France
- Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, pôle biologie, Paris F-75015, France
| | - P Laurent-Puig
- INSERM, U490, Université René Descartes, Paris F-75006, France
- Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, pôle biologie, Paris F-75015, France
- INSERM U490, Université René Descartes, 45 rue des Saints-Pères 75006, Paris, France; E-mail:
| |
Collapse
|
49
|
Blons H, Feldmann D, Duval V, Messaz O, Denoyelle F, Loundon N, Sergout-Allaoui A, Houang M, Duriez F, Lacombe D, Delobel B, Leman J, Catros H, Journel H, Drouin-Garraud V, Obstoy MF, Toutain A, Oden S, Toublanc JE, Couderc R, Petit C, Garabédian EN, Marlin S. Screening of SLC26A4 (PDS) gene in Pendred's syndrome: a large spectrum of mutations in France and phenotypic heterogeneity. Clin Genet 2004; 66:333-40. [PMID: 15355436 DOI: 10.1111/j.1399-0004.2004.00296.x] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Sensorineural hearing defect and goiter are common features of Pendred's syndrome. The clinical diagnosis of Pendred's syndrome remains difficult because of the lack of sensitivity and specificity of the thyroid signs. The identification of PDS as the causative gene allowed molecular screening and enabled a re-evaluation of the syndrome to identify potential diagnostic characteristics. This report presents the clinical and genotypic findings of 30 French families, for whom a diagnosis of Pendred's syndrome had been made. Twenty-seven families had at least one mutated allele. Twenty-eight different mutations were identified, 11 of which had never been previously reported. The main clinical characteristics were: early hearing loss, fluctuation in terms of during deafness evolution, and the presence of an enlarged vestibular aqueduct.
Collapse
Affiliation(s)
- H Blons
- Service de biochimie et de biologie moléculaire, Hôpital d'Enfants Armnd-Trousseau, AP-HP, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Blons H, Laccourreye O, Laurent-Puig P. [Cellular and neoplastic otorhinolaryngologic changes, molecular markers and therapeutic potential]. Ann Otolaryngol Chir Cervicofac 2003; 120:152-60. [PMID: 12843984] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/03/2023]
Abstract
Head and neck cancer is believed to arise after accumulation of genetic alterations resulting at least partially from chronic exposure of the upper aerodigestive tract to tobacco carcinogens. Accumulation of somatic genetic events in genes implicated in cell growth and differentiation lead to cell transformation and to the acquisition of cancer phenotype. The most frequent alterations in head and neck cancer results from chromosomal instability with amplification and deletion of recurrent chromosome arms. Among the genes that drives head and neck carcinogenesis, TP53 mutations, p16 deletion or hypermethylation, amplification of cyclinD1 and overexpression of the epidermal growth factor receptor are of the most importance and will be discuss in this review. Correlation between genetic alterations and clinical parameters will be underlined. Indeed, the identification of molecular alterations linked to specific tumor parameters may be of help in the management of head and neck cancer patients or useful in the development of new therapeutic strategies. Finally, studies have shown that in some part, constitutional genetic background could also interfere with the development of head and neck cancer through the existence of polymorphisms in carcinogens metabolizing enzymes and/or DNA repair enzymes. Individuals with low carcinogens elimination or DNA repair capacities could therefore be at risk of head and neck cancer. In this review both aspects of head and neck carcinogenesis will be discuss and relation between fundamental research and clinical practice will be mentioned.
Collapse
Affiliation(s)
- H Blons
- U490 INSERM Laboratoire de Toxicologie Moléculaire, 45 rue des Saints Pères, 75006 Paris
| | | | | |
Collapse
|